ReWalk Robotics Reports Second Quarter 2017 Financial Results -- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million - -- 11 favorable commercial case-by-case insurance

Robotics Reports Second Quarter 2017 Financial Results

-- 146% YOY growth in Q2 revenue to $2 million and

record 1H revenue of $4.5 million -

-- 11 favorable commercial case-by-case insurance

coverage decisions --

-- 217 pending insurance claims in the U.S. and Germany

-- Unveiled Restore soft-exosuit for stroke patients

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 3, 2017 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk"

or "the Company") today announced its financial results for the three- and six-month periods ended June 30, 2017.

Highlights of and subsequent to the second quarter include:

"This was another strong quarter

for ReWalk as we advanced our key initiatives: securing insurance reimbursement coverage for the ReWalk personal device, expanding

our global footprint and progressing our innovative soft suit' exoskeleton technology designed for individuals with

stroke. We've submitted extensive data for review by a large commercial insurer in the U.S. and await a decision. We believe

that a positive coverage decision would be an important catalyst for our business and the industry. It would also reflect the growing

consensus among multiple courts and insurers who have determined, on a case by case basis, that our technology is not experimental

and offers health benefits to its users," stated Larry Jasinski, Chief Executive Officer.

"At the same time, we are excited

to have introduced our Restore lightweight soft suit' design for stroke patients. We plan to begin clinical studies

and pursue regulatory approvals so that we can commercialize the Restore in 2018, in order to broaden the reach of our technology

to the millions of patients who can benefit from access to the device," he added.

Second Quarter 2017 Financial

Total revenue was $2 million for the

second quarter of 2017, an increase of 146% compared with $817,000 in the second quarter of 2016. 31 ReWalk units were placed during

the second quarter, compared with 25 ReWalk systems placed in the prior year period, of which 17 were placed in the U.S., 11 in

Europe, and three with distributors.

Gross margin improved to 37% during

the second quarter of 2017 compared to 10% in the prior year period, primarily attributable to the increase in volume, conversion

of rental units to purchases, and lower product costs.

Total operating expenses in the second

quarter of 2017 were $6.1 million compared with $8.7 million in the second quarter of 2016. Operating

expenses in the second quarter of 2017 reflect initiatives to reduce spending announced earlier in 2017. Second quarter 2016 expenses

include a one-time R&D charge related to the licensing agreement with the Wyss Institute at Harvard University.

Net loss was $6.3 million for the second

quarter of 2017 compared with a net loss of $9.1 million in the prior year quarter. Non-GAAP net loss for the second quarter was

$4.9 million compared with a non-GAAP net loss of $8.0 million in the second quarter of 2016.*

*A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of June 30, 2017, ReWalk had $16.3

million in cash on its balance sheet.

ReWalk management will host its second

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 47740857.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic

exoskeletons for individuals with spinal cord injury. ReWalk's

mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development

of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information

on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities

Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and,

in some cases, may be identified by words like "anticipate," "assume," "believe," "continue,"

"could," "estimate," "expect," "intend," "may," "plan,"

"potential," "predict," "project," "future," "will," "should,"

"would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release

are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that

are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's

actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's

expectations regarding future growth, including its ability to increase sales in its existing geographic markets, expand to new

markets and achieve its planned expense reductions; the conclusion of ReWalk's management for the financial statements for

the second quarter of 2017 and for fiscal 2016, and the opinion of ReWalk's auditors in their report on the Company's

financial statements for fiscal 2016, that there are substantial doubts as to ReWalk's ability to continue as a going concern;

ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to

achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program

and clinical results; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential

regulatory developments with respect to, ReWalk's mandatory post-market 522 surveillance study; the outcome of ongoing shareholder

class action litigation relating to ReWalk's initial public offering; ReWalk's ability to repay its secured indebtedness;

ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection

of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain

and maintain regulatory approvals; ReWalk's ability to secure capital from its equity and debt financings in light of limitations

under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings

may dilute ReWalk's shareholders or restrict its business; ReWalk's ability to use effectively the proceeds of its

2016 follow-on offering; ReWalk's ability to maintain relationships with existing customers and develop relationships with

new customers; the impact of the market price of ReWalk's ordinary shares on the determination of whether ReWalk is a passive

foreign investment company; ReWalk's compliance with medical device reporting regulations to report adverse events involving

its products and the potential impact of such adverse events on ReWalk's ability to market and sell its products; and other

factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year ended

December 31, 2016, as amended, filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with

or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only

as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained

herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk

undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted

Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP net loss is helpful to its investors. This measure is not

prepared in accordance with GAAP.

For the three- and six-months ended June 30, 2017 and 2016,

non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and

(iii) non-cash financial expenses.

Because of varying available valuation methodologies, subjective

assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, ReWalk believes that providing

non-GAAP net loss that excludes non-cash share-based compensation expense, depreciation and non-cash financial (income) expenses

allows for more meaningful comparisons between operating results from period to period. This non-GAAP financial measure is an important

tool for financial and operational decision-making and for the Company's evaluation of its operating results over different